Squamous cell carcinoma of the head and neck in nonsmokers: Clinical and biologic characteristics and implications for management

Current Opinion in Oncology

Volumn 13, Issue 3, 2001, Pages 176-182

  Lingen, Mark ^a   Sturgis, Erich M ^b   Kies, Merrill S ^c,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Departments of Head and Neck Surgery   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALCOHOL ABUSE; DISEASE ASSOCIATION; HEAD CANCER; HIGH RISK PATIENT; HUMAN; NECK CANCER; OROPHARYNX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; TONGUE;

ADULT; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 0035041502     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200105000-00008     Document Type: Review

References (74)

1. 1 Cancer Statistics 2000. CA Cancer J Clin 2000, 50.
2. 2 Vokes EE, Weichselbaum RR, Lippman SM, et al.: Head and neck cancer. N Engl J Med 1993, 328:184-194.
3. 3 Hong WK, Lippman SM, Wolf GT: Recent advances in head and neck cancer: larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993, 53:5113-5120.
4. 4 Vokes EE, Haraf DJ, Kies MS: The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 2000, 27:34-38.
5. 5 Kies MS, Haraf DJ, Athanasiadis I, et al.: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998, 16:2715-2721.
6. 6 Brizel DM, Albers ME, Fisher SR, et al.: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
7. 7 Calais G, Alfonsi M, Bardet E, et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
8. 8 Vokes EE, Kies MS, Haraf DJ, et al.: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000, 18:1652-1661.
9. 9 List MA, Siston A, Haraf DJ, et al.: Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999, 17:1020-1028.
10. 10 Byers RM: Squamous cell carcinoma of the oral tongue in patients less than thirty years of age. Am J Surg 1975, 130:475-478.
11. 11 Newman AN, Rice DH, Ossoff RH, et al.: Carcinoma of the tongue in persons younger than 30 years of age. Arch Otolaryngol 1983, 109:302-304.
12. 12 McGregor GI, Davis N, Robins RE: Squamous cell carcinoma of the tongue and lower oral cavity in patients under 40 years of age. Am J Surg 1983, 146:88-92.
13. 13 Cusumano RJ, Persky MS: Squamous cell carcinoma of the oral cavity and oropharynx in young adults. Head Neck Surg 1988, 10:229-234.
14. 14 Shemen LJ, Klotz J, Schottenfeld D, et al.: Increase of tongue cancer in young men [letter]. JAMA 1984, 252:1857.
15. 15 Atula S, Grenman R, Laippala P, et al.: Cancer of the tongue in patients younger than 40 years: a distinct entity? Arch Otolaryngol Head Neck Surg 1996, 122:1313-1319.
16. 16 Myers JN, Elkins T, Roberts D, et al.: Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 2000, 1222:44-51.
17. 17 Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993, 7:139-146.
18. 18 Field JK: Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer 1992, 28B:67-76.
19. 19 Todd R, Donoff RB, Wong DT: The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg 1997, 55:613-623; discussion 623-615.
20. 20 Wong DT, Todd R, Tsuji T, et al.: Molecular biology of human oral cancer. Crit Rev Oral Biol Med 1996, 7:319-328.
21. 21 Califano J, van der Riet P, Westra W, et al.: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56:2488-2492.
22. 22 Wiencke JK, Thurston SW, Kelsey KT, et al.: Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst 1999, 91:614-619. This work demonstrates that young persons may be particularly susceptible to DNA adduct formation and persistence, relative to smokers who started smoking in later years.
23. 23 Fioretti F, Bosetti C, Tavani A, et al.: Risk factors for oral and pharyngeal cancer in never smokers. Oral Oncol 1999, 35:375-378.
24. 24 Gisser SD: Papovavirus and squamous cell carcinoma. Hum Pathol 1981, 12:190-193.
25. 25 Maden C, Beckmann AM, Thomas DB, et al.: Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 1992, 135:1093-1102.
26. 26 Gillison ML, Koch WM, Shah KV: Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 1999, 11:191-199.
27. 27 Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720. Reports data strongly indicating strongly that HPV-positive oropharyngeal cancers comprise a distinctive clinicopathologic disease associated causally with HPV infection and a relatively favorable prognosis.
28. 28 Franceschi S, Munoz N, Bosch XF, et al.: Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996, 5:567-575.
29. 29 Fouret P, Monceaux G, Temam S, et al.: Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 1997, 123:513-516.
30. 30 Lee YW, Gisser SD: Squamous cell carcinoma of the tongue in a nine year renal transplant survivor: a case report with a discussion of the risk of developmentof epithelial carcinomas in renal transplant survivors. Cancer 1978, 41:1-6.
31. 31 Pollard JD, Hanasono MM, Mikulec AA, et al.; Head and neck cancer in cardiothoracic transplant recipients. Laryngoscope 2000, 110:1257-1261.
32. 32 Yagi K, Ali Ae-G, Abbas Ke-D, et al.: Carcinoma of the tongue in a patient with xeroderma pigmentosum. Int J Oral Surg 1981, 10:73-76.
33. 33 Harper JI, Copeman PW: Carcinoma of the tongue in a boy with xeroderma pigmentosum. Clin Exp Dermatol 1981, 6:601-604.
34. 34 Baden HP, Alper JC: Ichthyosiform dermatosis, keratitis, and deafness. Arch Dermatol 1977, 113:1701-1704.
35. 35 Keukens F, van Voorst Vader PC, Panders AK, et al.: Xeroderma pigmentosum: squamous cell carcinoma of the tongue. Acta Derm Venereol 1989, 69:530-531.
36. 36 Wade MH, Plotnick H: Xeroderma pigmentosum and squamous cell carcinoma of the tongue: identification of two black patients as members of complementation group C. J Am Acad Dermatol 1985, 12:515-521.
37. 37 Tashiro H, Abe K, Tanioka H: Familial occurrence of cancer of the mouth. J Oral Maxillofac Surg 1986, 44:322-323.
38. 38 Hara H, Ozeki S, Shiratsuchi Y, et al.: Familial occurrence of oral cancer: report of cases. J Oral Maxillofac Surg 1988, 46:1098-1102.
39. 39 Cloos J, Spitz MR, Schantz SP, et al.: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996, 88:530-535.
40. 40 Bartek J, Bartkova J, Vojtesek B, et al.: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991, 6:1699-1703.
41. 41 Greenblatt MS, Bennett WP, Hollstein M, et al.: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878.
42. 42 Girod SC, Krueger G, Pape HD: p53 and Ki 67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int J Oral Maxillofac Surg 1993, 22:285-288.
43. 43 Boyle JO, Hakim J, Koch W, et al.: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993, 53:4477-4480.
44. 44 Field JK, Spandidos DA, Malliri A, et al.: Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991, 64:573-577.
45. 45 Westra WH, Offerhaus GJ, Goodman SN, et al.: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993, 17:213-220.
46. 46 Brennan JA, Boyle JO, Koch WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332:712-717.
47. 47 Lazarus P, Garewal HS, Sciubba J, et al.: A low incidence of p53 mutations in pre-malignant lesions of the oral cavity from non-tobacco users. Int J Cancer 1995, 60:458-463.
48. 48 Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Genes Dev 1990, 4:1-8.
49. 49 Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991, 351:453-456.
50. 50 Dees C, Godfrey VL, Foster JS, et al.: Stabilization of the p53 gene product in two bovine leukemia virus infected cell lines, Cancer Lett 1994, 86:33-40.
51. 51 Reid RL, Lindholm PF, Mireskandari A, et al.: Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 1993, 8:3029-3036.
52. 52 Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993, 7:535-545.
53. 53 Momand J, Zambetti GP. Olson DC, et al.: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
54. 54 Sorensen DM, Lewark TM, Haney JL, et al.: Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. Arch Otolaryngol Head Neck Surg 1997, 123:503-506.
55. 55 Lingen MW, Chang KW, McMurray SJ, et al.: Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck 2000, 22:328-335. We reported that p53 was overexpressed in 81% of tumors from a series of 21 never-smokers. Mutations commonly related to tobacco exposure were not observed.
56. 56 Ohgaki H, Eibl RH, Schwab M, et al.: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993, 8:74-80.
57. 57 Ellison DW, Lunec J, Gallagher PJ, et al.: Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 1995, 21:136-142.
58. 58 Mor O, Yaron P, Huszar M, et al.: Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997, 16:9-13.
59. 59 Ungar S, Van de Meeren A, Tammilehto L, et al.: High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 1996, 74:1534-1540.
60. 60 Jin Y, Mertens F, Mandahl N, et al.: Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 1993, 53:2140-2146.
61. 61 Nawroz H, van der Riet P, Hruban RH, et al.: Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994, 54:1152-1155.
62. 62 Li X, Lee NK, Ye YW, et al.: Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994, 86:1524-1529.
63. 63 Schantz SP, Hsu TC, Ainslie N, et al.: Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA 1989, 262:3313-3315.
64. 64 Wang LE, Sturgis EM, Eicher SA, et al.: Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 1998, 4:1773-1778.
65. 66 Cheng L, Sturgis EM, Eicher SA, et al.: Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999, 84:220-224. Patients with SCCHN are more commonly polymorphic for two glutathione-S-transferases, GSTT1 and GSTM1, than the population in general. The highest frequency of these two polymorphisms or their combination was seen in patients under the age of 45 years.
66. 66 Sturgis EM, Castillo EJ, Li L, et al.: Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999, 20:2125-2129. Patients with SCCHN are more commonly homozygous for the codon 399 polymorphism of the DNA repair gene XRCC1 than the population in general. The highest frequency of this polymorphism was in patients under the age of 50 years.
67. 67 Cheng L, Eicher SA, Guo Z, et al.: Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 7:465-468.
68. 68 Mendez P Jr, Maves MD, Panje WR: Squamous cell carcinoma of the head and neck in patients under 40 years of age. Arch Otolaryngol 1985, 111:762-764.
69. 69 Lydiatt DD, Robbins KT, Byers RM, et al.; Treatment of stage I and II oral tongue cancer. Head Neck 1993, 15:308-312.
70. 70 Friedlander PL, Schantz SP, Shaha AR, et al.: Squamous cell carcinoma of the tongue in young patients: a matched-pair analysis. Head Neck 1998, 20:363-368.
71. 71 Siegelmann-Danieli N, Hanlon A, Ridge JA, et al.: Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients. J Clin Oncol 1998, 16:745-753.
72. 72 Yoshida K, Koizumi M, Inoue T, et al.: Radiotherapy of early tongue cancer in patients less than 40 years old. Int J Radiat Oncol Biol Phys 1999, 45:367-371.
73. 73 Verschuur HP, Irish JC, O'Sullivan B, et al.: A matched control study of treatment outcome in young patients with squamous cell carcinoma of the head and neck. Laryngoscope 1999, 109:249-258. This matched analysis of patients with SCCHN suggested that patients under 40 years of age do not have a worse survival.
74. 74 Pitman KT, Johnson JT, Wagner RL, et al.: Cancer of the tongue in patients less than forty. Head Neck 2000, 22:297-302. This meta-analysis shows no difference in treatment outcomes at 3-year follow-up.